Company: PSTV
Filing Date: 2025-04-11
Form Type: POS AM
Source: 0001193125-25-079109
Chunk: 14

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-11
Form: POS AM
Chunk 14
---
” do not reflect 576,525 March 2025 Series A Warrants and                
 576,525 March 2025 Series B Warrants issued pursuant to the March Purchase Agreement, which are not exercisable unless and until we obtain the approval of our stockholders. Iroquois Capital Management L.L.C. is the investment manager of Iroquois     
 Master Fund, Ltd. Iroquois Capital Management, LLC has voting control and investment discretion over securities held by Iroquois Master Fund. As Managing Members of Iroquois Capital Management, LLC. Richard Abbe and Kimberly Page make voting and     
 investment decisions on behalf of Iroquois Capital Management, LLC in its capacity as investment manager to Iroquois Master Fund Ltd. As a result of the foregoing, Mr. Abbe and Mrs. Page may be deemed to have beneficial ownership (as                 
 determined under Section 13(d) of the Securities Exchange Act) of the securities held by Iroquois Capital Management and Iroquois Master Fund. The address for Iroquois Master Fund Ltd., Mr. Abbe and Mrs. Page is c/o Iroquois Capital                  
 Management, LLC, 2 Overhill Road, Suite 400, Scarsdale, New York 10583.                                                                                                                                                                                   |

| (5) | The shares reported under “Beneficial Ownership Before this Offering” consist of the following                                                                                                                                                      
 securities purchased by Iroquois Capital Investment Group LLC in the May 2024 PIPE Financing: (i) 29,875 shares of common stock; and (ii) 586,987 shares of common stock issuable upon the exercise of Series B Common Stock Warrants. The Series B 
 Common Stock Warrants are subject to a beneficial ownership limitation of                                                                                                                                                                           |

7

| 4.99%, which limitation restricts the selling stockholder from exercising that portion of the Series B Common Stock Warrants that would result in the selling stockholder and its affiliates                                               
 owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The shares reported under “Beneficial Ownership Before this Offering” do not reflect 880,780 March 2025 Series A Warrants and 
 880,780 March 2025 Series B Warrants issued pursuant to the March Purchase Agreement, which are not exercisable unless and until we obtain the approval of our stockholders. Mr. Richard Abbe is the managing member of Iroquois Capital   
 Investment Group